NLRP3 inflammasome: potential role in obesity related low-grade inflammation and insulin resistance in skeletal muscle
Author
dc.contributor.author
Jorquera, Gonzalo
Author
dc.contributor.author
Russell, Javier
Author
dc.contributor.author
Monsalves Álvarez, Matías
Author
dc.contributor.author
Cruz, Gonzalo
Author
dc.contributor.author
Valladares-Ide, Denisse
Author
dc.contributor.author
Basualto Alarcón, Carla Edith
Author
dc.contributor.author
Barrientos, Genaro
Author
dc.contributor.author
Estrada, Manuel
Author
dc.contributor.author
Llanos, Paola
Admission date
dc.date.accessioned
2021-12-07T18:48:38Z
Available date
dc.date.available
2021-12-07T18:48:38Z
Publication date
dc.date.issued
2021
Cita de ítem
dc.identifier.citation
Int. J. Mol. Sci. 2021, 22, 3254
es_ES
Identifier
dc.identifier.other
10.3390/ijms22063254
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/183114
Abstract
dc.description.abstract
Among multiple mechanisms, low-grade inflammation is critical for the development of insulin resistance as a feature of type 2 diabetes. The nucleotide-binding oligomerization domain-like receptor family (NOD-like) pyrin domain containing 3 (NLRP3) inflammasome has been linked to the development of insulin resistance in various tissues; however, its role in the development of insulin resistance in the skeletal muscle has not been explored in depth. Currently, there is limited evidence that supports the pathological role of NLRP3 inflammasome activation in glucose handling in the skeletal muscle of obese individuals. Here, we have centered our focus on insulin signaling in skeletal muscle, which is the main site of postprandial glucose disposal in humans. We discuss the current evidence showing that the NLRP3 inflammasome disturbs glucose homeostasis. We also review how NLRP3-associated interleukin and its gasdermin D-mediated efflux could affect insulin-dependent intracellular pathways. Finally, we address pharmacological NLRP3 inhibitors that may have a therapeutical use in obesity-related metabolic alterations.
es_ES
Patrocinador
dc.description.sponsorship
FONDECYT-ANID 1190406
REDES170032
1201816
11190949
Centro de Neurobiologia y Fisiopatologia Integrativa (CENFI), Universidad de Valparaiso Grant DIUV-CI 01/2006
es_ES
Lenguage
dc.language.iso
en
es_ES
Publisher
dc.publisher
MDPI
es_ES
Type of license
dc.rights
Attribution-NonCommercial-NoDerivs 3.0 United States